CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

Clinical safety rating: safe

May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.

How it works

Clindamycin phosphate is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. Benzoyl peroxide is an oxidizing agent with bactericidal activity against Propionibacterium acnes, and also has keratolytic and comedolytic effects.

What the body does with it

Metabolism	Clindamycin phosphate is hydrolyzed to clindamycin; clindamycin is primarily metabolized by CYP3A4 and to a lesser extent by CYP3A5. Benzoyl peroxide is metabolized to benzoic acid and then excreted in urine.
Excretion	Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin. After topical application, systemic absorption is minimal (approximately 10% of applied dose). The absorbed clindamycin is primarily excreted via the kidneys (10% unchanged, 3% as metabolites) and biliary/fecal routes (approximately 4%). Benzoyl peroxide is converted to benzoic acid, which is up to 87% excreted in urine as hippuric acid after conjugation with glycine. Overall, for the combination, renal excretion accounts for ~10%, biliary/fecal ~4%, remainder remains unabsorbed or metabolized locally.
Half-life	Terminal elimination half-life of clindamycin after topical application is approximately 2.4 hours. However, due to slow release from skin depot, effective half-life extends to 6–12 hours, supporting twice-daily dosing. Benzoyl peroxide has a very short half-life (<1 minute) on skin due to rapid decomposition; systemic half-life of benzoic acid is ~0.9 hours.
Protein binding	Clindamycin is 60–94% bound to serum proteins (mainly albumin). Benzoyl peroxide is not systemically absorbed in significant amounts; its metabolite benzoic acid is 20–40% bound to albumin.
Volume of Distribution	For clindamycin, apparent volume of distribution is approximately 0.6–1.2 L/kg. With topical application, the systemic Vd is low due to limited absorption. Benzoyl peroxide is not systemically distributed.
Bioavailability	Topical: Clindamycin phosphate systemic bioavailability is about <5% (range 1–10%) after application to intact skin. Benzoyl peroxide bioavailability is negligible (<1%) as it is converted to benzoic acid on the skin; benzoic acid may be absorbed with bioavailability of ~5% but rapidly metabolized.
Onset of Action	Clinical effect (reduction of inflammatory lesions) is typically observed within 2–4 weeks of twice-daily topical application. Initial improvement may be seen as early as 2 weeks, with maximal effect at 10–12 weeks.
Duration of Action	After cessation of application, clindamycin's antibacterial effect persists for approximately 24–48 hours due to tissue binding and slow release. Benzoyl peroxide has no residual antimicrobial effect beyond the application period. The clinical duration of effect (lesion reduction) lasts for several weeks, but sustained use is required to maintain control.

Classification & Brands

Dosing & administration

Apply a thin film to affected areas twice daily (morning and evening).

Dosage form	GEL
Renal impairment	No adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, use with caution due to limited data.
Liver impairment	No dosage adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A and B). Safety and efficacy not established in severe hepatic impairment (Child-Pugh C).
Pediatric use	Approved for children ≥12 years: apply thin film to affected areas twice daily. For children <12 years: safety and efficacy not established.
Geriatric use	No specific dose adjustment required; however, elderly patients may have increased sensitivity to local adverse effects. Use with caution.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.

FDA category	Human
Breastfeeding	Clindamycin: Excreted in breast milk; M/P ratio approximately 0.1-0.6. Cases of bloody stools and diarrhea in breastfed infants reported. Benzoyl peroxide: Not absorbed systemically; unlikely to be excreted. Use with caution; discontinue breastfeeding if infant develops gastrointestinal symptoms.
Teratogenic Risk

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Common Effects	Diarrhea (including C. difficile)
Serious Effects

Absolute Contraindications

["History of regional enteritis, ulcerative colitis, or antibiotic-associated colitis due to clindamycin.","Hypersensitivity to clindamycin, benzoyl peroxide, or any component of the formulation."]

Clinical Precautions

Precautions

["Clostridium difficile associated diarrhea (CDAD) may occur with topical clindamycin; if diarrhea occurs, discontinue use.","Avoid contact with eyes, mouth, lips, and mucous membranes.","May cause skin irritation, erythema, peeling, and dryness; reduce frequency or discontinue if severe.","Concomitant use with other topical acne products may increase irritation.","Use caution in patients with history of colitis or inflammatory bowel disease."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

Clinical safety rating: safe

May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.

How it works

What the body does with it

Metabolism	Clindamycin phosphate is hydrolyzed to clindamycin; clindamycin is primarily metabolized by CYP3A4 and to a lesser extent by CYP3A5. Benzoyl peroxide is metabolized to benzoic acid and then excreted in urine.
Excretion	Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin. After topical application, systemic absorption is minimal (approximately 10% of applied dose). The absorbed clindamycin is primarily excreted via the kidneys (10% unchanged, 3% as metabolites) and biliary/fecal routes (approximately 4%). Benzoyl peroxide is converted to benzoic acid, which is up to 87% excreted in urine as hippuric acid after conjugation with glycine. Overall, for the combination, renal excretion accounts for ~10%, biliary/fecal ~4%, remainder remains unabsorbed or metabolized locally.
Half-life	Terminal elimination half-life of clindamycin after topical application is approximately 2.4 hours. However, due to slow release from skin depot, effective half-life extends to 6–12 hours, supporting twice-daily dosing. Benzoyl peroxide has a very short half-life (<1 minute) on skin due to rapid decomposition; systemic half-life of benzoic acid is ~0.9 hours.
Protein binding	Clindamycin is 60–94% bound to serum proteins (mainly albumin). Benzoyl peroxide is not systemically absorbed in significant amounts; its metabolite benzoic acid is 20–40% bound to albumin.
Volume of Distribution	For clindamycin, apparent volume of distribution is approximately 0.6–1.2 L/kg. With topical application, the systemic Vd is low due to limited absorption. Benzoyl peroxide is not systemically distributed.
Bioavailability	Topical: Clindamycin phosphate systemic bioavailability is about <5% (range 1–10%) after application to intact skin. Benzoyl peroxide bioavailability is negligible (<1%) as it is converted to benzoic acid on the skin; benzoic acid may be absorbed with bioavailability of ~5% but rapidly metabolized.
Onset of Action	Clinical effect (reduction of inflammatory lesions) is typically observed within 2–4 weeks of twice-daily topical application. Initial improvement may be seen as early as 2 weeks, with maximal effect at 10–12 weeks.
Duration of Action	After cessation of application, clindamycin's antibacterial effect persists for approximately 24–48 hours due to tissue binding and slow release. Benzoyl peroxide has no residual antimicrobial effect beyond the application period. The clinical duration of effect (lesion reduction) lasts for several weeks, but sustained use is required to maintain control.

Classification & Brands

Dosing & administration

Apply a thin film to affected areas twice daily (morning and evening).

Dosage form	GEL
Renal impairment	No adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, use with caution due to limited data.
Liver impairment	No dosage adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A and B). Safety and efficacy not established in severe hepatic impairment (Child-Pugh C).
Pediatric use	Approved for children ≥12 years: apply thin film to affected areas twice daily. For children <12 years: safety and efficacy not established.
Geriatric use	No specific dose adjustment required; however, elderly patients may have increased sensitivity to local adverse effects. Use with caution.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.

FDA category	Human
Breastfeeding	Clindamycin: Excreted in breast milk; M/P ratio approximately 0.1-0.6. Cases of bloody stools and diarrhea in breastfed infants reported. Benzoyl peroxide: Not absorbed systemically; unlikely to be excreted. Use with caution; discontinue breastfeeding if infant develops gastrointestinal symptoms.
Teratogenic Risk

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Common Effects	Diarrhea (including C. difficile)
Serious Effects

Absolute Contraindications

["History of regional enteritis, ulcerative colitis, or antibiotic-associated colitis due to clindamycin.","Hypersensitivity to clindamycin, benzoyl peroxide, or any component of the formulation."]